In conclusion, our study demonstrated that both ABCB1 and ABCC11 were able to confer resistance to eribulin; we also showed that increased expression of both ABCB1 and ABCC11 may be involved in the development of eribulin resistance in breast cancer cells, regardless of the subtype. Here, ABCB1 is linked to breast carcinoma.